 Felly we know that not all patients are the same and so what the doctors and the scientists have been trying to do is trying to work out ways that we can separate patients into different groups and decide which treatment a certain patient should have. So we can do that based on their age but also based on different scientific results from the different tests that we take when we see a patient. Y mirogiciwch erbyn i'r marcau hon yn ystod y dyma'r marco bwrdd yma hyn y bydd y marglu yma y mylod yn saf, dwy'r colleg iawn. Mae'n cael ei bud o'r hunach, oherwydd o'r mahreig o'r bobl. A oedd gennyn ei wneud i mewn gwirionedd o gweithio ymarferwyr a th�� yma yw y marwyr o'r bobl o'r meddurell o'r marwyr, o rydyn ni'n gofynbwys i'r mylod yn fawr o'n mylod. Jo, mae angen ein prynsianrhaen o mewn mwyloi yn ymweld, gallwn dweud yw ein bod nhw'n edrych i fy nhw a i'r unigod o'ch mewn mwyloi. A roeddwn i ddweud yma yn eistedd ar rhan o twyd. Cyngorol i dda'r nifer o ddweud ychydig. Llywodraeth imbryd llawer ar y dyfodol ar gyfer i dda'r marwau newydd. Angwy wedi ddwych fy mwyloi hwnnw yn unig o plasmysau. Ac mae'n gweithio'r cwmwysgau geneddwys yn cylleg iawn, ac mae'r cwmwysgau yn cael ei wneud yn gweithio'r cwmwysgau. Mae'r cyfnodau rhan o'r wneud newyddau cyfnogi yn cael ei wneud yn cwmwysgau ddefnyddio'r cyfnodau cyfnodau cyfnodau, ac mae'n cwmwysgau eich gwneud a'u gwneud o'r cyfnodau. Mae'r cyfnodau yn gweithio iawn i gael o'r centau yma, ac mae'n gwybod i'n gweithio iawn, boeddwn yn cyffinio i'w hwnnw i'w ar hyn o'is wahanol i chi i'w ddweud i gael byddoch i wneud y gweithreidolternau fel y cyfnodol. Y rhaid i gweithio gwlaeth clynyddol yn gwirioneddol, mae'n cael ei ddweud i'w ddweud og adnolmallystydd yn ffynnolau Ysgrifawr. Mae'n gweithio i gweld i'w adnolmallystydd i'w gweithreidolternau ym mwyn i ddweud yn gweldio ac oes yn cyffredinol yn gwneud yn mynd i chi. Felly, yn y gallu ei bod yn fwy o maen nhw'n gwneud. Rydyn ni'n gweithio'r gweithio'r gweithio'n gweithio'n gwybod a'r adnomalau cyd-dweithr nesaf y cyfrifoedd y 414, ond mae'r testau yng nghydfyrdd yn wneud y ffwysig. those patients may respond particularly well to Bortesimib or Velcaid treatment, whereas other patients, for example patients who have a deletion of a particular gene called 17p, those patients may not respond so well. So, by doing these different tests we can hopefully identify which patients will respond well to a drug, and which patients may maybe won't respond so well, and so therefore should have a different kind of drug. Felly, we've been able to identify lots of different markers that will give us some clues as to which drugs work best for different patients. And now, we've got many what we call targeted drugs, which are drugs which will specifically work on a specific kind of myeloma. And so an example is a drug that was originally developed for melanoma, the skin cancer. And not a number of patients with myeloma actually have the same abnormality as those patients that have melanoma, the skin cancer. And so what we've been able to do is to use the melanoma drug to treat myeloma patients. Now, it's only a small percentage of patients that have that abnormality, but we're beginning to get more and more abnormalities that we can identify, and therefore more and more drugs that we could use specifically for different kinds of patients. So what we're going to have to do is to really work with the laboratories based in our hospitals, because at the moment we'll often choose a treatment and say we think this is the best treatment. But what we're going to have to do is just as the moment we maybe send our full blood count off to the lab or our kidney test off to the lab, we're going to need to develop a whole infrastructure in the lab that's able to characterise these different abnormalities so that when we maybe do a bone marrow, three days later we know so much about that patient we can say this is the best treatment for them. So we need to start a good dialogue with our laboratories to make sure that they're capable of doing these tests to really help us direct our therapy.